Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status

J. M. Cunningham, M. S. Cicek, N. B. Larson, J. Davila, C. Wang, M. C. Larson, H. Song, E. M. Dicks, P. Harrington, M. Wick, B. J. Winterhoff, H. Hamidi, G. E. Konecny, J. Chien, M. Bibikova, J. B. Fan, K. R. Kalli, N. M. Lindor, B. L. Fridley, P. P.D. PharoahE. L. Goode

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Abstract

We evaluated homologous recombination deficient (HRD) phenotypes in epithelial ovarian cancer (EOC) considering BRCA1, BRCA2, and RAD51C in a large well-annotated patient set. We evaluated EOC patients for germline deleterious mutations (n = 899), somatic mutations (n = 279) and epigenetic alterations (n = 482) in these genes using NGS and genome-wide methylation arrays. Deleterious germline mutations were identified in 32 (3.6%) patients for BRCA1, in 28 (3.1%) for BRCA2 and in 26 (2.9%) for RAD51C. Ten somatically sequenced patients had deleterious alterations, six (2.1%) in BRCA1 and four (1.4%) in BRCA2. Fifty two patients (10.8%) had methylated BRCA1 or RAD51C. HRD patients with germline or somatic alterations in any gene were more likely to be high grade serous, have an earlier diagnosis age and have ovarian and/or breast cancer family history. The HRD phenotype was most common in high grade serous EOC. Identification of EOC patients with an HRD phenotype may help tailor specific therapies.

Original languageEnglish (US)
Article number4026
JournalScientific reports
Volume4
DOIs
StatePublished - Feb 7 2014

Bibliographical note

Funding Information:
This work was supported by National Institutes of Health grants R01-CA122443, P50-CA136393, P30-CA15083, and the Fred C. and Katherine B. Andersen Foundation. We thank Gary Kenney, M.D. for pathology review of tumor tissue. We thank Craig Luccarini, Caroline Baynes from University of Cambridge for assisting our sample sequencing.

Fingerprint Dive into the research topics of 'Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status'. Together they form a unique fingerprint.

Cite this